[Dimethyl fumarate (relapsing remitting multiple sclerosis) –Benefit assessment according to §35a Social Code Book V]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005244
German
Original Title:
Dimethylfumarat (multiple Sklerose bei Kindern und Jugendlichen ab 13 Jahren)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-68.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-68_dimethylfumarat_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
DOI:
10.60584/A23-68
MeSH Terms
- Multiple Sclerosis, Relapsing-Remitting
- Child
- Adolescent
- Immunosuppressive Agents
Keywords
- Multiple Sclerosis – Relapsing-Remitting
- Child
- Adolescent
- Benefit Assessment
- NCT02283853
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.